Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.450
+0.120 (9.02%)
At close: Feb 10, 2026, 4:00 PM EST
1.400
-0.050 (-3.45%)
After-hours: Feb 10, 2026, 7:54 PM EST
Entera Bio Revenue
Entera Bio had revenue of $124.00K in the twelve months ending September 30, 2025. In the year 2024, Entera Bio had annual revenue of $181.00K.
Revenue (ttm)
$124.00K
Revenue Growth
+25.25%
P/S Ratio
536.23
Revenue / Employee
$5,636
Employees
22
Market Cap
66.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CervoMed | 6.16M |
| Plus Therapeutics | 5.26M |
| Lipocine | 4.32M |
| NeurAxis | 3.36M |
| Aligos Therapeutics | 2.65M |
| Impact BioMedical | 25.00K |
ENTX News
- 1 day ago - Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones - GlobeNewsWire
- 7 weeks ago - Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation - GlobeNewsWire
- 7 weeks ago - Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) - GlobeNewsWire
- 3 months ago - Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference - GlobeNewsWire
- 3 months ago - Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women - GlobeNewsWire
- 4 months ago - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting - GlobeNewsWire
- 6 months ago - Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 months ago - Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis - GlobeNewsWire